Discussion
Mosliciguat, an inhaled treatment being developed by Pulmovant, was well tolerated and more effective than a placebo at improving blood flow through the lungs of adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD), supporting its move into Phase 3 clinical testing, which is already underway. That’s…